Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advances in the treatment of non-Hodgkin's lymphoma.
Cerny T, Gillessen S. Cerny T, et al. Among authors: gillessen s. Ann Oncol. 2002;13 Suppl 4:211-6. doi: 10.1093/annonc/mdf662. Ann Oncol. 2002. PMID: 12401693 Free article. Review. No abstract available.
Thalidomide: from tragedy to promise.
von Moos R, Stolz R, Cerny T, Gillessen S. von Moos R, et al. Among authors: gillessen s. Swiss Med Wkly. 2003 Feb 8;133(5-6):77-87. doi: 10.4414/smw.2003.09947. Swiss Med Wkly. 2003. PMID: 12644961 Free article. Review.
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Morant R, Bernhard J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J, Cerny T, Rochlitz C, Wernli M, Gschwend A, Hanselmann S, Hering F, Schmid HP. Morant R, et al. Among authors: gillessen s. Br J Cancer. 2004 Apr 5;90(7):1312-7. doi: 10.1038/sj.bjc.6601673. Br J Cancer. 2004. PMID: 15054447 Free PMC article. Clinical Trial.
[Mabthera for treatment of malignant lymphoma].
Cerny T, Hitz F, Gillessen S. Cerny T, et al. Among authors: gillessen s. Ther Umsch. 2004 Jun;61(6):379-83. doi: 10.1024/0040-5930.61.6.379. Ther Umsch. 2004. PMID: 15253163 Review. German.
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M. Jermann M, et al. Among authors: gillessen s. Cancer Chemother Pharmacol. 2006 Apr;57(4):533-9. doi: 10.1007/s00280-005-0070-z. Epub 2005 Jul 29. Cancer Chemother Pharmacol. 2006. PMID: 16052341 Free article. Clinical Trial.
Hypertriglyceridemia as a possible risk factor for prostate cancer.
Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, Krek W, Cerny T, Gillessen S. Wuermli L, et al. Among authors: gillessen s. Prostate Cancer Prostatic Dis. 2005;8(4):316-20. doi: 10.1038/sj.pcan.4500834. Prostate Cancer Prostatic Dis. 2005. PMID: 16158078
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. Waeckerle-Men Y, et al. Among authors: gillessen s. Cancer Immunol Immunother. 2006 Dec;55(12):1524-33. doi: 10.1007/s00262-006-0157-3. Epub 2006 Apr 13. Cancer Immunol Immunother. 2006. PMID: 16612599 Free PMC article. Clinical Trial.
303 results